Company intelligence / Profile preview
Giaconda Limited
Sydney, New South Wales, Australiagiacondalimited.com ↗
- Ownership
- Public · ASX:GIA
- Development stage
- Other
01
Overview
Giaconda developed novel combinations of known compounds for gastrointestinal conditions. Their lead product Myoconda completed a Phase III trial for Crohn's Disease with 213 patients across 20 centers in Australia. Hepaconda showed improvement in liver function in Phase II trials.
- Therapeutic areas
- GastroenterologyInfectious Diseases
- Modalities
- Drug combinations
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Forest Laboratories (non-binding letter of intent for UK and Irish market)Pharmacia (option agreement)RedHill Biopharma (acquired three products)Ind Swift Laboratories (supply and manufacture agreement for Myoconda)
Beyond the preview
Go deeper on Giaconda Limited.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Giaconda Limited.